Heartflow, Inc. Common Stock HTFL

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

• GlobeNewswire Inc. 17 sept

  Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive Landscape

  The global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.

  

• GlobeNewswire Inc. 28 ago

  Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half

  Heartflow announced one-year results from the independent FUSION trial showing its FFRCT Analysis reduced unnecessary invasive heart procedures by 44% when added to standard CCTA scans. The Dutch government-funded randomized controlled trial of 528 patients demonstrated that Heartflow's AI technology safely bridges diagnostic gaps in coronary artery disease evaluation, maintaining identical revascularization rates while significantly reducing diagnostic catheterizations.

  

• The Motley Fool 14 ago

  Why Heartflow Stock Soared Today

  Heartflow stock jumped 35.70% after the medical diagnostics company raised its full-year revenue guidance to $246-250 million (40-42% growth) from a prior forecast of 29-32% growth. The company's Q2 revenue surged 48% year-over-year to $64.1 million, with adjusted gross margins improving to 83.3% from 75.6%, demonstrating improving profitability and operational scalability.

  

• The Motley Fool 15 jul

  What Does the HeartFlow CEO's Sale of Over 20,000 Company Shares Mean for Investors?

  HeartFlow CEO John Farquhar sold 22,562 shares worth ~$626,100 on July 10, 2026, as part of a pre-arranged Rule 10b5-1 trading plan established in September 2025. The sale represents only a 5% reduction in his direct holdings, and he retains 435,373 shares valued at $11.63 million, indicating aligned interests with shareholders. The transaction is not considered a red flag given its non-discretionary nature and the company's strong Q1 performance with 41% year-over-year revenue growth.

  

• The Motley Fool 8 jul

  Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?

  Heartflow, an AI-driven diagnostic platform, shows strong 40% revenue growth but faces reimbursement headwinds and remains unprofitable. Omeros is transitioning to commercial stage with its newly approved drug Yartemlea, posting early Q1 2026 revenue of $9.89 million. The article recommends Omeros as the safer bet for 2026 despite trading at a premium, citing its transition to profitability versus Heartflow's expected positive free cash flow not until 2028.